Dr. Benjamin Tjoa presents this ePoster, highlighting data emphasizing the importance of antigen presentation in selecting an antigen for targeting by the immune system. Several T cells lines specific for common tumor antigens were developed, with the aim to understand the cytotoxic capability of the T cells and the degree to which these tumor antigens are presented by HLA class I molecules. The IncuCyte® live cell imaging system was used to measure the cytotoxic ability of tumor specific T cells using appropriate tumor cell lines as targets.
About the Presenter
Vice President, R&D Cellero, A Charles River Company
Benjamin Tjoa received his Ph.D. in Biochemistry/Immunology from the University of Illinois at Urbana-Champaign. With over 20 years of experience, Dr. Tjoa has held various positions in R&D, product development, and translational research. Prior to Charles River, he was VP in Research and Technology for Astarte Biologics/Cellero, leading them in research and product development, planning, quality testing and production of all Astarte/Cellero's immune cell products for research.